Emergent BioSolutions (EBS) Q4 2025 earnings summary

Executive summary

• Achieved FY 2025 revenues of $743 million, driven by strong MCM sales and effective management of naloxone products, despite Q4 headwinds from a prolonged U.S. government shutdown and a 29% year-over-year revenue decline.

• Returned to profitability in 2025 with net income of $52.6 million versus a net loss of $190.6 million in 2024; adjusted net income for 2025 was $86.8 million, a significant turnaround from an adjusted net loss of $12.1 million in 2024.

• Adjusted EBITDA for 2025 reached $205 million (28% margin), up 12% year-over-year and at the high end of guidance, with significant improvements in cash flow and liquidity.

• Continued execution of a multi-year transformation plan, including strategic divestitures, margin improvements, debt reduction, and share repurchases to enhance shareholder value.

• Maintained market leadership in naloxone, with over 100 million doses distributed since 2016 and new product launches supporting growth.

Financial highlights

• FY 2025 revenues were $743 million, down from $1,044 million in 2024, reflecting divestitures and normalization after one-time settlements; Q4 revenues were $149 million.

• Adjusted EBITDA grew to $205 million (28% margin), up from $183 million (18% margin) in 2024.

• Adjusted gross margin improved to 54% from 45% year-over-year; operating expenses reduced by $140 million versus 2024.

• Adjusted net income per diluted share for 2025 was $1.53, up from a loss of $0.23 in 2024.

• Year-end cash stood at $205 million, with total liquidity of $305 million.

Outlook and guidance

• 2026 revenue guidance: $720 million–$760 million; Q1 2026 revenue guidance is $135 million–$155 million.

• MCM revenue expected flat to slightly down; commercial revenues flat to slightly up.

• Adjusted EBITDA guidance: $135 million–$155 million; adjusted gross margin: 45%–47%.

• Net income expected between a loss of $30 million and a loss of $10 million; adjusted net income between $25 million and $45 million.

• Key assumptions include R&D at 6–7% of revenues, SG&A at 26–28% of revenues, and capex of ~$17 million.